Lithium, which is still the gold standard in the treatment of bipolar disorder, has been proposed to inhibit inositol monophosphatase (IMPase) and is hypothesized to exert its therapeutic effects by attenuating phosphatidylinositol (PI) cell signalling. Drug-discovery efforts have focused on small-molecule lithium mimetics that would specifically inhibit IMPase without exhibiting the undesired side effects of lithium. L-690,330 is a potent bisphosphonate substrate-based inhibitor developed by Merck Sharp & Dohme. To aid future structure-based inhibitor design, determination of the exact binding mechanism of L-690,330 to IMPase was of interest. Here, the high-resolution X-ray structure of human IMPase in complex with L690,330 and manganese ions determined at 1.39 Å resolution is reported.
Introduction
IMPase (EC 3.1.3.25) is a highly conserved enzyme of the phosphatidylinositol (PI) signalling cascade that hydrolyses inositol monophosphate to yield free inositol and phosphate (Ackermann et al., 1987) . The PI pathway is primarily activated by G-coupled proteins that activate phospholipase C (PLC). PLC hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). Binding of IP 3 to the IP 3 receptor (IP 3 -R) promotes the release of calcium from intracellular calcium stores into the cytoplasm, while DAG activates protein kinase C (PKC). Subsequently, IP 3 is converted by a series of kinases and phosphatases to a variety of inositol phosphates that are involved in intracellular signalling. PIP 2 is regenerated mainly by the recycling of IP 3 by different phosphatases that sequentially dephosphorylate IP 3 to free inositol. Inositol is then converted by another series of enzymes to phosphatidylinositol (PI), phosphatidylinositol phosphate (PIP) and PIP 2 (Free et al., 2007; Majerus, 1992; Gould & Manji, 2002; Gani et al., 1993) . IMPase is the last and rate-limiting phosphatase in the recycling of PIP 2 and hence is a crucial enzyme in the PI cycle.
The IMPase enzyme assembles as a homodimer and requires magnesium as a cofactor for its catalytic activity; however, it is inhibited by high concentrations of magnesium and calcium, as well as by therapeutic lithium (Hallcher & Sherman, 1980) . Inhibition of IMPase by lithium led to Berridge's 'inositol depletion hypothesis', in which attenuation of PI signalling is a result of inositol depletion and in turn leads to impaired PI recycling and production (Berridge et al., 1989) .
IMPase therefore presents an interesting therapeutic target for bipolar disorder (BPD). Great efforts were made to ISSN 2059-7983 # 2018 International Union of Crystallography develop potent substrate-based inhibitors of IMPase by Merck Sharp & Dohme in the 1990s. Unfortunately, most of these compounds (for example L-690,330 and L-693,369) possessed low bioavailability, although the esterified prodrug L-690,488 had favourable penetrability and mimicked the effect of lithium on the PI pathway in human cell lines . Interestingly, intracerebroventricular liposomal administration of L-690,330 ameliorated epilepsy in a mouse model, with behaviour in the forced swim test mirroring that of mice treated with oral lithium (Shtein et al., 2013) . Recent advances in drug-delivery systems may stimulate renewed interest in these potent and specific inhibitors of IMPase for the treatment of BPD.
The determination of X-ray structures of IMPase in complex with these inhibitors would shed light on their binding mechanism and provide valuable insights for the improvement of their potency and bioavailability. Here, we report the first crystal structures of human IMPase in complex with L-690,330 determined at 1.39 Å resolution.
Methods

Materials
All reagents were purchased from Sigma-Aldrich or Fisher Scientific unless stated otherwise. Ampicillin was purchased from Melford and L-690,330 from Tocris Bioscience.
Preparation of recombinant human IMPase
The gene encoding human IMPase with an amino-terminal six-histidine tag separated by an HRV 3C protease cleavage site was synthesized and subcloned into a pET-15b vector by GenScript. The expression of recombinant human IMPase has been described elsewhere (Singh et al., 2012) . A starter culture of transformed Escherichia coli Rosetta2 (DE3) cells (Merck Millipore) was grown overnight in Luria-Bertani (LB) medium containing 50 mg ml À1 ampicillin and 35 mg ml À1 chloramphenicol at 37 C with shaking at 200 rev min À1 . Cells from this culture were used to inoculate 2 l LB medium containing 2.5 mM betaine, 660 mM sorbitol, 50 mg ml À1 ampicillin and 35 mg ml À1 chloramphenicol, and were grown at 37 C to an OD 600 of $0.2-0.3. The temperature was then reduced to 25 C and the culture was further propagated until the OD 600 reached $0.6. IMPase expression was induced by the addition of 0.4 mM isopropyl -d-1-thiogalactopyranoside (IPTG) and the culture was grown overnight at 25 C with shaking at 180 rev min À1 . The cells were pelleted by centrifugation at 9600g for 20 min at 4 C and resuspended in 50 ml lysis buffer [20 mM Tris-HCl pH 7.8, 150 mM NaCl, 40 U ml À1 DNAse I and one EDTA-free protease-inhibitor tablet (Thermo Scientific) per 50 ml]. The pellet was lysed by ultrasonication (5 s sonication, 5 s break, 6 min total sonication time, 39% amplitude; Vibra cell sonicator VCX500, Sonics) and the cellular debris was pelleted by centrifugation at 33 000g for 20 min at 4 C. The clarified sonicate was heattreated at 68 C for 1 h and the precipitated protein was pelleted by centrifugation at 32 000g for 20 min at 4 C. The supernatant was then incubated at 4 C for 1 h with TALON Superflow resin (GE Healthcare) that had been pre-equilibrated with binding buffer (20 mM Tris-HCl pH 7.8, 150 mM NaCl, 10 mM imidazole). After incubation, the resin was washed with seven resin volumes (RV) of wash buffer (20 mM Tris-HCl pH 7.8, 150 mM NaCl, 15 mM imidazole) and the histidine-tag-bound IMPase was eluted with 5 RV of elution buffer (20 mM Tris-HCl pH 7.8, 150 mM NaCl, 250 mM imidazole). The elution fractions were pooled and the histidine tag was cleaved overnight at 4 C by the addition of PreScission protease (see below) at a protease:protein ratio of 1:100(w:w). After digestion, PreScission protease was separated from IMPase by incubating the digestion mixture with Glutathione Sepharose 4 Fast Flow resin (GE Healthcare) that had been pre-equilibrated with size-exclusion chromatography (SEC) buffer (20 mM Tris-HCl pH 7.8, 150 mM NaCl). The collected flowthrough was concentrated to 5 ml using Vivaspin 15R concentrators (molecular-weight cutoff 10 000, Sartorius Stedim) at 4000g and 4 C and was then loaded onto a HiLoad 26/600 Superdex 75 prep-grade SEC column (GE Healthcare) pre-equilbrated with SEC buffer. SEC was performed on an Ä KTA FPLC system (GE Healthcare). Proteins were gel-filtered at a flow rate of 2.5 ml min À1 and the eluted fractions were analysed by SDS-PAGE using NuPAGE Novex 4-12% Bis-Tris protein gels (Life Technologies). Fractions containing IMPase were pooled, concentrated and buffer-exchanged into storage buffer [20 mM Tris-HCl pH 7.8, 150 mM NaCl, 1 mM EDTA, 10%(v/v) glycerol] using Vivaspin 15R concentrators (molecular-weight cutoff 10 000, Sartorius Stedim) at 4000g and 4 C.
Preparation of PreScission protease
A synthetic gene for glutathione S-transferase (GST)tagged HRV 3C protease (PreScission protease) was cloned into pGEX-1 (GE Healthcare). Transformed E. coli Rosetta2 (DE3) cells were used to inoculate a 200 ml starter culture of LB medium supplemented with 50 mg ml À1 ampicillin and 35 mg ml À1 chloramphenicol and the culture was propogated overnight at 37 C with shaking at 200 rev min À1 . 40 ml of the overnight starter culture was used to inoculate 2 l shake-flask cultures and was incubated with shaking at 180 rev min À1 to an OD 600 of $0.6. Flasks were placed on ice for 15 min, induced with 0.2 mM IPTG and grown overnight at 20 C with shaking at 180 rev min À1 . The cells were harvested by centrifugation at 9600g for 20 min at 4 C, resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 1000 mM NaCl, 1 mM EDTA, 1 mM DTT) and lysed by ultrasonication (see above). Cell debris was pelleted by centrifugation at 32 000g for 20 min at 4 C and the supernatant was loaded onto a GST Trap FF column (GE Healthcare) pre-equilibrated with lysis buffer. The column was extensively washed with lysis buffer and the protein was eluted with 10 mM reduced glutathione in lysis buffer. Fractions were analysed by SDS-PAGE and fractions containing fusion protein were pooled and dialyzed overnight into storage buffer [50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM EDTA, 1 mM DTT, 20%(v/v) glycerol].
Malachite green assay and differential scanning fluorimetry (DSF)
The inhibitory effect of L-690,330 on human IMPase was tested using the malachite green assay (D'Angelo et al., 2001; O'Toole et al., 2007; Itaya & Ui, 1966) . A ten-point doseresponse curve was recorded to determine the inhibitory concentration of L-690,330 (IC 50 ). For this, L-690,330 (highest concentration 30 mM) was added to 0.08 ng ml À1 IMPase in assay buffer [50 mM Tris-HCl pH 7.4, 3 mM MgCl 2 , 150 mM KCl, 0.5 mg ml À1 bovine serum albumin (BSA), 0.01%(w/v) Triton X-100] and incubated at room temperature for 10 min. 0.075 mM inositol 1-phosphate was then added and incubated at 37 C for 30 min; the reaction was then stopped and phosphate formation was detected by adding BIOMOL GREEN solution (Enzo Life Science). The plate was incubated at room temperature for 30 min and the absorbance was measured at = 630 nm on a PHERAstar FS plate reader (BMG Labtech). Data were analyzed and plotted with GraphPad Prism 7.0.2 (GraphPad).
To determine the melting points of IMPase in the presence of L-690,330, the inhibitor (highest concentration 30 mM) was mixed with 6 mM IMPase in DSF assay buffer (50 mM HEPES pH 7.4, 3 mM MgCl 2 , 150 mM KCl, 1 mM EGTA) and incubated at room temperature for 10 min. 4Â SYPRO Orange dye (Sigma-Aldrich) was then added and melting curves were recorded on a LightCycler 480 II (Roche). To determine the melting point of the holoenzyme on its own, IMPase at different concentrations in DSF buffer was mixed with 4Â SYPRO Orange dye and the melting curve was directly recorded. The integration time was set manually to 1 s. The temperature was held at 20 C for 1 min and then increased by 1 C every 0.4 min up to a maximum temperature of 95 C. Data were integrated and analysed using the LightCycler 480 software v.1.5 (Roche) and the melting points were determined manually.
Crystallization
Crystallization of human IMPase was carried out in VDX plates (Hampton Research) using the hanging-drop method or in two-well MRC plates (Swissci) using the sitting-drop method.
To crystallize human IMPase in the presence of manganese, equal volumes (1 ml) of the target protein in storage buffer (20 mg ml À1 ) and reservoir solution [0.12 M MnSO 4 , 0.1 M 2-(N-morpholino)ethanolsulfonic acid (MES) pH 5.5, 24%(w/v) PEG 4000] were mixed and incubated at room temperature for a few days.
Human IMPase in complex with L-690,330 was crystallized at room temperature using the hanging-drop method and microseeding. Seeds were obtained from the crystals described above using the Seed Bead kit from Hampton Research. Human IMPase in storage buffer (20 mg ml À1 ) was first incubated at 37 C for 15 min in the presence of 5 mM L-690,330 previously dissolved in storage buffer. Equal volumes (1 ml) of the enzyme-inhibitor mixture and reservoir solution [0.2 M MnSO 4 , 0.1 M MES pH 5.5, 25%(w/v) PEG 4000] containing seeds (diluted 1:100 in reservoir solution) were then mixed and incubated at room temperature for a few days.
All crystals were cryoprotected by transfer from 0 to 30%(v/v) glycerol in steps of 10% prior to flash-cooling in liquid nitrogen and data collection. X-ray diffraction data were collected on beamlines I02 ( = 0.9795 Å ) and I04 ( = 0.9141 Å ) at Diamond Light Source, Oxfordshire, England using a Dectris PILATUS 6M-F detector. The crystals were cooled to 100 K during data collection by a cryostream (Oxford Cryosystems). Data were integrated and scaled using the automatic processing program xia2 (Winter, 2010) at Diamond Light Source.
Phases were obtained by molecular replacement using PHENIX (Adams et al., 2010) . For the structure with manganese and MES in the active site, the published structure of human IMPase (PDB entry 4as4; Singh et al., 2012) was used in the usual space group (P3 2 21). For the structure in complex with L-690,330, the refined manganese-and MESbound structure was used as the model.
Data were processed with the CCP4 suite (Winn et al., 2011) , PHENIX (Adams et al., 2010) and BUSTER (Bricogne et al., 2011) , and manual rebuilding was performed in Coot (Emsley et al., 2010) . All pictures were generated in Maestro 11.3 (Schrö dinger). The protein models were prepared using the integrated protein-preparation wizard in Maestro: bond orders were assigned, H atoms were added, zero-order bonds to metals and disulfide bonds were created, and waters at a distance of more than 5 Å from hetero groups were deleted. Additionally, the protein was refined by assigning hydrogen bonds at pH 7.0.
Results and discussion
3.1. L-690,330 significantly increases the thermal stability of IMPase
The 2-, 6-and 4-hydroxyl groups of Ins1P are important for binding to IMPase (Baker et al., 1989 (Baker et al., , 1990 . Accordingly, a series of phenolic bisphosphonate-containing inhibitors were synthesized, with L-690,330 having one of the highest affinities for IMPase . Here, we determine the inhibitory effect of L-690,330 on IMPase using the malachite green assay for phosphate detection. The inhibitory concentration (IC 50 ) of 0.22 AE 0.01 mM (Fig. 1b) compares well with the previously cited value of 0.27 mM (Atack et al., 1993) .
The binding of L-690,330 to IMPase was further characterized by differential scanning fluorimetry (DSF). The unfolding and exposure of hydrophobic residues in proteins with increased temperature can be monitored by DSF through dyes that bind and fluoresce in nonpolar environments, allowing the melting point (T m ) to be determined. Small molecules that bind to the protein often stabilize it and shift the melting point to higher temperatures (Niesen et al., 2007) . IMPase on its own has a remarkably high melting point of 79 C (Fig. 1a) , explaining why heat treatment is possible during purification without denaturing or precipitating the research papers protein (McAllister et al., 1992) . DSF reveals concentrationdependent stabilization of IMPase by L-690,330, with the protein melting point being increased by up to 15 C. Indeed, at the highest concentrations of L-690,330 the melting curve cannot be fully visualized (Fig. 1a) .
2-(N-Morpholino)ethanolsulfonic acid binds to the active site
To understand how L-690,330 inhibits IMPase function, we determined the crystal structure of the holoenzyme and also of the complex of the enzyme with L-690,330. Preliminary crystallization trials indicated that IMPase preferably crystallized in the presence of divalent ions (e.g. magnesium, calcium or manganese), a Good's buffer (e.g. MES, bis-Tris propane or Tris) and polyethylene glycol (PEG) 3350 or 4000 as a precipitant. A combination of MnSO 4 , MES at pH 5.5 and PEG 4000 yielded large and well diffracting crystals.
The holo IMPase crystal diffracted to 1.79 Å resolution (Table 1 ) and contained two molecules in the asymmetric unit. Each monomer of the holo IMPase homodimer possesses the characteristic core structure (Bone et al., 1992) and coordinates three manganese ions, a MES molecule and a glycerol molecule in the active site (Fig. 2) . Structural superposition on the published structure of human IMPase (PDB entry 4as4; Singh et al., 2012) yielded an r.m.s.d. of 0.41 Å and showed identical co-location of the metal ions, as well as an identical orientation of the residues that form the substratebinding pocket. Thus, the binding of MES neither alters the geometry of the active site nor induces movement of the substrate-binding residues.
3.3. L-690,330 is stabilized by additional residues in the pocket Initial attempts to co-crystallize IMPase with L-690,330 failed because the DMSO in which L-690,330 was dissolved affected the crystal growth. Inclusion of the polar L-690,330 in the IMPase storage buffer before crystallization resolved this issue.
The IMPase-L-690,330 crystal structure was determined at 1.39 Å resolution (Table 1) and is the highest resolution human IMPase structure to date. There are no significant secondarystructural differences compared with the holo structure determined with MES ( Fig. 3b) Holoenzyme structure. (a) The structure of IMPase co-crystallized with manganese and MES and (b) this structure superposed on the previously published structure co-crystallized with magnesium (PDB entry 1as4). (c) The detailed structure of the holoenzyme active site. An MES molecule is coordinated via its sulfonic group to all three manganese ions and a glycerol (GOL) molecule mimics the inositol ring interaction of the substrate (see Fig. 3 ).
Figure 3
The at its active site (Fig. 3a) . The interaction of L-690,330 with the protein backbone is similar to that of the substrate Ins1P when compared with previously published structures (PDB entry 1awb; Fig. 3c ; Ganzhorn & Rondeau, 1997) . One key interaction is the hydrogen bond between the para O atom of the inhibitor and the carboxylate group of Glu213. All three manganese ions interact with the phosphonate groups of the inhibitor, and the extra phosphoryl group of L-690,330 interacts with the additional residues Trp219 and Asp220, which are likely to contribute to the tight binding of this inhibitor (Fig. 3a) . The active site of IMPase is larger than necessary to accommodate Ins1P, making it possible for the enzyme to hydrolyse a variety of other substrates (Gee et al., 1988; Attwood et al., 1988; Takimoto et al., 1985; Parthasarathy et al., 1997) . Our holo IMPase structure demonstrates the binding of an MES molecule, which interestingly is not orientated like Ins1P or L-690,330 but instead interacts with other parts of the pocket. This observation could potentially be utilized in the design of novel IMPase inhibitors that do not mimic the substrate. Additionally, our crystal structure in complex with L-690,330 could be used in a rational structure-based approach to improve its potency.
